Daraxonrasib extends survival in metastatic pancreatic cancer
1. Daraxonrasib is the first-in-class RAS inhibitor approved for metastatic pancreatic adenocarcinoma, addressing a molecular pathway that drives most pancreatic ...
Tag: daraxonrasib
2MM: Pharma Roundup – mRNA flu vaccine debuts, RAS inhibition extends pancreatic cancer survival, and new therapies advance for dermatomyositis and Tourette syndrome
mFlusiva outperforms standard-dose flu vaccine in adults 50 and older The U.S. Food and Drug Administration (FDA) approved mFlusiva (mRNA-1010) ...
Daraxonrasib showed antitumor activity in previously treated RAS-mutant non–small-cell lung cancer
1. In patients with previously treated advanced RAS-mutant non–small-cell lung cancer, daraxonrasib produced objective responses in approximately one-third of subjects ...
New targeted therapy daraxonrasib improves survival in pancreatic cancer
1. Daraxonrasib significantly improves survival in metastatic pancreatic cancer compared with standard chemotherapy. 2. Strong response rates in combination therapy ...
![2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]](https://www.2minutemedicine.com/wp-content/uploads/2025/05/ChatGPT-Image-May-12-2025-at-10_22_23-AM-350x250.png)
2 Minute Medicine: Pharma Roundup – Geopolitical instability in the Strait of Hormuz threatens global generic drug supply, daraxonrasib improves pancreatic cancer survival, sparsentan (Filspari) approved for focal segmental glomerulosclerosis, glucagon-like peptide-1 receptor agonists linked to reduced substance use disorders, and orforglipron (Foundayo) expands oral weight loss therapy options
Geopolitical instability in the Strait of Hormuz threatens global generic drug supply Ongoing escalations in the Strait of Hormuz have ...
